Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/Dual blockade increases hyperkalemia
Dual · ACEARB-DUAL-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
When an ACE inhibitor and an angiotensin-receptor blocker are given together, several large trials found more high-potassium events and more kidney harm than with one drug alone. The clearest single trial, NEPHRON-D in people with diabetic kidney disease [4], recorded both high potassium and acute kidney injury more often on the combination and was stopped early for safety. A very large trial, ONTARGET, found the same direction for high potassium [8] and for worsening kidney outcomes [1][2]. Two trials in narrower populations found no difference: one in polycystic kidney disease [6] and one smaller diabetic-nephropathy trial [7], with a dual-therapy blood-pressure study reporting the combination well tolerated [5]. The panel read the direction of harm as consistent and reproducible while noting that acute kidney injury itself is measured directly in only one trial and that one adequately sized trial saw no difference.
Across independent randomised trials the combination raised high-potassium events: NEPHRON-D [4] (6.3 vs 2.6 events per 100 person-years, P<0.001), the ONTARGET potassium post-hoc [8] (2.7% vs 1.6%, P<0.001) and Luño [12] (more frequent, P<0.001), with a feasibility study showing 15% hyperkalemia on dual therapy [9]. The kidney-harm signal rests most directly on NEPHRON-D's acute kidney injury endpoint [4] (12.2 vs 6.7 events per 100 person-years, P<0.001) and is corroborated by ONTARGET's worsened renal composite [1] (renal dysfunction 13.5% vs 10.2%, P<0.001) and doubling-of-creatinine or dialysis outcome [2] (HR 1.24, 1.01-1.51). NEPHRON-D was stopped early owing to safety concerns [4]. Against this, HALT-PKD [6] (N=486) found hyperkalemia and acute kidney injury similar between groups, and a smaller diabetic-nephropathy trial [7] (N=133) found adverse events including hyperkalemia similar across arms. The contested point: The division is over how general and how direct the harm is: the positive trials [4][8][12] show a reproducible direction, but one adequately sized trial [6] and a smaller one [7] found no difference, so universality across populations is disputed. The acute kidney injury half is contested because only NEPHRON-D [4] reports acute kidney injury as such, while ONTARGET's supporting endpoints [1][2] are chronic/progression measures rather than a clean acute injury definition.
All 26 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The effect is not universal: HALT-PKD [6] (N=486, adequately powered) found hyperkalemia and AKI 'similar in the two groups', and [7] and [5] report no safety signal — so the claim's generality across populations is overstated by the positive trials alone.
The AKI half of the claim rests heavily on one trial: only NEPHRON-D [4] reports acute kidney injury as such, in diabetic nephropathy; ONTARGET's supporting evidence [1][2] is 'renal dysfunction' and a dialysis/doubling-creatinine composite (CKD progression), which is indirect for acute kidney injury.
Where it remains uncertain. HALT-PKD [6] (N=486) found hyperkalemia and acute kidney injury similar between groups, and only NEPHRON-D [4] measures acute kidney injury directly, so generality and the acute-injury endpoint remain in question.
Aleatory
Hyperkalemia was uncommon in the largest trial (2.7% vs 1.6% [8]), so random variation in event counts shapes estimates, especially in the small trials [9][12].
Epistemic
Only NEPHRON-D [4] reports acute kidney injury as such; the quantity of direct acute-injury evidence is thin, leaving the AKI half reliant on one population.
The load-bearing papers from a corpus of 26, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest trial: combination increased renal dysfunction versus monotherapy.
“as compared with the ramipril group, there was an increased risk of hypotensive symptoms (4.8% vs. 1.7%, P<0.001), syncope (0.3% vs. 0.2%, P=0.03), and renal dysfunction (13.5% vs. 10.2%, P<0.001).”
Panel auditInternal validity: high · scope of inference: Patients with vascular disease or high-risk diabetes without heart failure; renal dysfunction as a safety event under dual blockade.Key limitations: hyperkalemia not reported in this abstract · 'renal dysfunction' not defined as AKI per se · population at high vascular risk, not nephropathy cohort
Combination worsened major renal outcomes in the largest trial.
“The secondary renal outcome, dialysis or doubling of serum creatinine, was similar with telmisartan (189 [2.21%]) and ramipril (174 [2.03%]; HR 1.09, 0.89-1.34) and more frequent with combination therapy (212 [2.49%]: HR 1.24, 1.01-1.51, p=0.038).”
Panel auditInternal validity: high · scope of inference: People at high vascular risk; hard renal outcomes rather than acute kidney injury specifically.Key limitations: renal composite is chronic hard endpoints, not AKI episodes · no hyperkalemia data in this abstract · high-vascular-risk, not nephropathy, population
Most direct support — single RCT showing both hyperkalemia and AKI increased, stopped early for safety.
“Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001).”
Panel auditInternal validity: high · scope of inference: Type 2 diabetes with established diabetic nephropathy (macroalbuminuria, eGFR 30-89.9); the most direct test of the exact claim.Key limitations: stopped early, so effect estimates on efficacy are immature · nephropathy population may overstate risk vs general use
Counter-evidence: adequately powered ADPKD RCT found no increase in hyperkalemia or AKI.
“The rates of decline in the estimated GFR, urinary albumin excretion, and other secondary outcomes and adverse events, including hyperkalemia and acute kidney injury, were also similar in the two groups.”
Panel auditInternal validity: high · scope of inference: ADPKD patients aged 18-64 with stage 3 CKD; a tightly controlled, BP-matched population.Key limitations: ADPKD-specific, younger population · adverse-event comparison stated qualitatively without rates in abstract
4 of 26 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, reproducible harm across the major trials supports the claim at the Established floor, held down by the single adequately-powered null [6] and the indirectness of ONTARGET's renal endpoints for acute kidney injury.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Direct AKI endpoints outside diabetic nephropathy. Acute kidney injury as such is reported only by NEPHRON-D [4] in diabetic nephropathy; the ADPKD null [6] and ONTARGET's indirect endpoints [1][2] leave the acute-injury half population-bound. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A trial or pooled analysis with a pre-specified acute kidney injury definition in non-diabetic CKD populations receiving dual blockade.
Open question: Does dual ACEi plus ARB raise acute kidney injury in populations other than diabetic nephropathy? Why it is still open: Only NEPHRON-D [4] measures acute kidney injury directly and only in diabetic nephropathy; HALT-PKD [6] in ADPKD found no difference.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19